Skip to content

Physical Exercise for Breast Cancer Survivors: Face-to-face Versus Home-based

Pilot Study of Supervised Adapted Physical Exercise in Women With Breast Cancer After Treatment - Face-to-face Context vs Online Home Based

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05071560
Acronym
On4Rehab
Enrollment
12
Registered
2021-10-08
Start date
2021-05-01
Completion date
2021-09-30
Last updated
2022-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The present investigation is a pilot feasibility study that aims to compare a physical exercise intervention in a face-to-face context (considered state of the art) with a physical exercise intervention in a distance context (online), both supervised, in women, of legal age, physically inactive, breast cancer survivors after primary treatment with curative intent. Before and after the intervention these women will have a physical and functional assessment, as well as a pre-trial cardiopulmonary exercise test, to check if there are safety conditions to participate and also to self tailor the exercise prescription. The prescription follows the ACSM´s exercise guidelines for cancer survivors and will comprise a 8 week combined exercise training, 3 times per week, in which two of them will be supervised and the third session of the week (cardio session) won´t. Chat´s and weekly personal messages, as well as education, will be used to promote retention and exercise adherence.

Interventions

Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start. The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019).

Sponsors

Centro Hospitalar de Vila Nova de Gaia/Espinho
CollaboratorOTHER
Universidad Europea de Madrid
CollaboratorOTHER
University Institute of Maia
CollaboratorOTHER
Associacao de Investigacao de Cuidados de Suporte em Oncologia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Pilot randomized controlled study

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women * Over legal age * With diagnosis of breast carcinoma between stages 0 and IIIc * ECOG 0 to 1 * Undergoing primary treatment with curative intent (surgery associated or not, with chemotherapy and / or adjuvant radiotherapy) for at least one month * With follow-up on medical oncology consultation at CHVNG/E * With consent of the attending oncologist for the practice of physical exercise * Non-compliance with current physical activity guidelines recommended by the ACSM (moderate aerobic activity\> = 150 min / week or vigorous\> = 75 min / week and \> = 2 strength training sessions / week) * With cognitive capacity to understand the project proposal

Exclusion criteria

* Severe anaemia seen in the last 3 months (Hb \<= 8g / dl) or moderate (Hb\> 8 and \<= 10 g / dl) symptomatic (sustained tachycardia, exertional dyspnea, chest pain or syncope), * Uncontrolled arterial hypertension (HTN grade 3-4 (CTCAE v.5)) (SAD\> = 160mmHg and / or DAD\> = 100mmHg) and / or potentially fatal consequences (malignant HTN, transient or permanent neurological deficit or hypertensive crisis) * Uncontrolled diabetes mellitus * Known cardiac or respiratory pathology * Any other contraindication given by the physiatrist and / or assistant surgeon

Design outcomes

Primary

MeasureTime frameDescription
Retention rateEnd of the intervention (week 9)The percentage of included patients who ended the program
Adherence rateEnd of the intervention (week 9)Number of absences to the sessions and number of completed sessions
Training tolerance regarding the duration of the exercise prescriptionDuring all intervention sessions (24 sessions, 8 weeks)Recording adherence to the exercise prescription duration, possible adjustments and their reasons
Training tolerance regarding the intensity of the exercise prescriptionDuring all intervention sessions (24 sessions, 8 weeks)Recording adherence to the exercise prescription intensity, possible adjustments and their reasons
Training tolerance regarding the volume of the exercise prescriptionDuring all intervention sessions (24 sessions, 8 weeks)Recording adherence to the exercise prescription volume, possible adjustments and their reasons
Intervention Recruitment RateBeginning of the intervention (week 0)Number of invitations made versus accepted (invitation made by the assistant oncologist)
Training safetyDuring all intervention sessions (24 sessions, 8 weeks)Recording symptoms and adverse effects
Absence and dropoutEnd of the intervention (week 9)Rate of absence from sessions and dropout of the program
Level of satisfactionEnd of the intervention (week 9)Questionnaire at the end of the intervention, from 1 to 5, where 1 is not satisfied and 5 is very satisfied

Secondary

MeasureTime frameDescription
Body heightBeginning (week 0) and End of the intervention (week 9)Height (m)
Body circumferencesBeginning (week 0) and End of the intervention (week 9)Waist circumference (cm), hip circumference (cm), middle crural circumference (cm) and bicipital circumference (cm)
Individual's overall satisfaction with life and general sense of personal well-beingBeginning (week 0) and End of the intervention (week 9)Questionnaire QLQ-C30
Individual's overall satisfaction with life and general sense of personal well-being, specific to breast cancer patientBeginning (week 0) and End of the intervention (week 9)Questionnaire QLQ-BR23
Adverse effectsDuring all intervention sessions (24 sessions, 8 weeks)Common Terminology Criteria for Adverse Effects, version 5, scale (presence of fatigue, osteoarticular and cardiac complaints, pain, neuropathy and lymphedema), ranging from 1 (mild, asymptomatic ou mild symptoms) to 5 (dead related to adverse event)
Cardiopulmonary system fitness level and signs of disease assessmentBeginning of the intervention (week 0)Measurement of maximum VO2 by a cardiopulmonary exercise test and assessment of cardiopulmonary risk factors or disease
Heart FunctionBeginning of the intervention (week 0)Resting heart rate (bpm)
Arterial disorder assessmentBeginning of the intervention (week 0)Systolic and diastolic blood pressure assessment (mm/hg)
Physical activity and sedentary behaviorsBeginning (week 0) and End of the intervention (week 9)Accelerometry
Subjective perception of effortDuring all intervention sessions (24 sessions, 8 weeks)Borg scale of perceived exertion ranging from 6 (very, very light effort) to 20 (maximum exertion)
Assessment of performance statusDuring all intervention sessions (24 sessions, 8 weeks)ECOG scale of performance status, in a scale ranging from 0 (fully active, able to carry same activities as before disease without new restrictions) to 5 (dead)
Lower limb strengthBeginning (week 0) and End of the intervention (week 9)30´´Sit to stand test (number of repetitions)
Upper limb strenghtBeginning (week 0) and End of the intervention (week 9)Bilateral handgrip test with dynamometer (kg)
Lower limbs flexibility levelBeginning (week 0) and End of the intervention (week 9)Sit and Reach test (cm)
Static balanceBeginning (week 0) and End of the intervention (week 9)One Leg Stance test (time, s)
Dynamic balance and agilityBeginning (week 0) and End of the intervention (week 9)8 Foot up and go test (time, s)
Assessment of aerobic capacityBeginning (week 0) and End of the intervention (week 9)6 Minute Walk Test
Safety of the interventionDuring all intervention sessions (24 sessions, 8 weeks)Number of serious and less serious occurrences
Body weightBeginning (week 0) and End of the intervention (week 9)Weight (Kg)

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026